StockIQ.techAstraZeneca PLC (AZN) Stock Analysis
Free AI-powered analysis and research for AstraZeneca PLC stock
Sector: Healthcare
AZN snapshot
Data as of 3 Nov 2026 close. Updated daily.
AstraZeneca PLC scores 72/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 51% of its 52-week range, up 12.4% over the past year. Latest reported figures show a profit margin of 17.0%, return on equity of 22.0% and revenue growth of +6.4%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Good Profit Margin (17.0%): +5
- Low Liquidity (0.89 Current Ratio): -10
- Excellent ROE (22.0%): +8
- High P/B (5.38): -5
- Above MA200: +4
- Up Over 1 Year (+12.4%): +3
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full AZN report
AstraZeneca PLC (AZN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze AZN Now →📰 Latest Update
RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines
Mon, November 2, 2026 at 3:50 PM UTC 4 min read
The global RNA targeting small molecule drug discovery market, valued at US$1.8 billion in 2024, is projected to reach US$5.3 billion by 2030, growing at a CAGR of 19.9%. Companies like AstraZeneca, Amgen, Roche, and Merck are accelerating their RNA-focused pipelines, leveraging advances in AI, structural biology, and high-throughput screening to create new therapeutic opportunities in oncology and rare diseases. The report highlights the increasing collaboration between biotech firms and pharmaceutical companies to address unmet medical needs through innovative RNA-targeted therapies.